Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Abreu

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
The Lancet. Rheumatology|January 30, 2024
Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumabVibeke Strand, Sean O'Quinn, Richard A Furie, et al.
The Lancet. Rheumatology|May 5, 2025
Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trialVibeke Strand, Kenneth C Kalunian, Kai Wai Lee, et al.
Rheumatology (Oxford, England)|August 26, 2022
Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trialsIan N Bruce, Ronald F van Vollenhoven, Eric F Morand, et al.
The Lancet. Rheumatology|January 27, 2024
Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 studyIan N Bruce, Alireza Nami, Erik Schwetje, et al.
Lupus|May 12, 2021
Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosusRichard Furie, Eric F Morand, Anca D Askanase, et al.
Modern Rheumatology|February 8, 2022
The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysisYoshiya Tanaka, Tatsuya Atsumi, Masato Okada, et al.
Journal of the American Society of Hypertension : JASH|December 3, 2014
The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trialGeorge D Kitas, Gabriel Abreu, Krystyna Jedrychowicz-Rosiak, et al.
Annals of the Rheumatic Diseases|February 13, 2025
LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trialsEric F Morand, Ronald van Vollenhoven, Richard A Furie, et al.
Modern Rheumatology|January 13, 2025
Disease activity and glucocorticoid tapering patterns in Japanese patients with systemic lupus erythematosus treated with anifrolumab: Post hoc analysis of the Japanese subpopulation of the TULIP-2 studyYoshiya Tanaka, Tatsuya Atsumi, Masato Okada, et al.
Annals of the Rheumatic Diseases|February 2, 2025
Reduced organ damage accumulation in adult patients with SLE on anifrolumab plus standard of care compared to real-world external controlsZahi Touma, Ian N Bruce, Richard Furie, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
The Lancet. Rheumatology|January 30, 2024
Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumabVibeke Strand, Sean O'Quinn, Richard A Furie, et al.
The Lancet. Rheumatology|May 5, 2025
Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trialVibeke Strand, Kenneth C Kalunian, Kai Wai Lee, et al.
Rheumatology (Oxford, England)|August 26, 2022
Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trialsIan N Bruce, Ronald F van Vollenhoven, Eric F Morand, et al.
The Lancet. Rheumatology|January 27, 2024
Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 studyIan N Bruce, Alireza Nami, Erik Schwetje, et al.
Lupus|May 12, 2021
Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosusRichard Furie, Eric F Morand, Anca D Askanase, et al.
Modern Rheumatology|February 8, 2022
The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysisYoshiya Tanaka, Tatsuya Atsumi, Masato Okada, et al.
Journal of the American Society of Hypertension : JASH|December 3, 2014
The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trialGeorge D Kitas, Gabriel Abreu, Krystyna Jedrychowicz-Rosiak, et al.
Annals of the Rheumatic Diseases|February 13, 2025
LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trialsEric F Morand, Ronald van Vollenhoven, Richard A Furie, et al.
Modern Rheumatology|January 13, 2025
Disease activity and glucocorticoid tapering patterns in Japanese patients with systemic lupus erythematosus treated with anifrolumab: Post hoc analysis of the Japanese subpopulation of the TULIP-2 studyYoshiya Tanaka, Tatsuya Atsumi, Masato Okada, et al.
Annals of the Rheumatic Diseases|February 2, 2025
Reduced organ damage accumulation in adult patients with SLE on anifrolumab plus standard of care compared to real-world external controlsZahi Touma, Ian N Bruce, Richard Furie, et al.
Pageof 3